Prognostic value of non-invasive fibrosis and steatosis tools, hepatic venous pressure gradient (HVPG) and histology in nonalcoholic steatohepatitis

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Sebastiani, Giada ^a   Alshaalan, Rasha ^a   Wong, Philip ^a   Rubino, Maria ^a   Salman, Ayat ^a   Metrakos, Peter ^a   Deschenes, Marc ^a   Ghali, Peter ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; GLUCOSE;

ACCURACY; ADULT; ALBUMIN BLOOD LEVEL; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; COHORT ANALYSIS; DISEASE MARKER; ELASTOGRAPHY; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HISTOLOGY; HUMAN; INCIDENCE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; VENOUS PRESSURE; AGED; CYTOCHEMISTRY; FIBROSIS; FOLLOW UP; LIVER; LIVER TRANSPLANTATION; MIDDLE AGED; MORTALITY; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PORTAL VEIN BLOOD PRESSURE; SURVIVAL ANALYSIS; VASCULARIZATION;

ADULT; AGED; AREA UNDER CURVE; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; HISTOCYTOCHEMISTRY; HUMANS; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PORTAL PRESSURE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84939195004     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128774     Document Type: Article

References (43)

1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55:2005-2023. doi: 10.1002/hep.25762 PMID: 22488764
2. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40:1387-1395. PMID: 15565570
3. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140:124-131. doi: 10.1053/j.gastro.2010.09.038 PMID: 20858492
4. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43:S99-S112. PMID: 16447287
5. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141:1249-1253. doi: 10.1053/j.gastro.2011.06.061 PMID: 21726509
6. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic Steatohepatitis is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the U.S. Gastroenterology 2014. Nov 25.
7. Friedman SL. Liver fibrosis-from bench to bedside. J Hepatol 2003; 38 Suppl 1: S38-53. PMID: 12591185
8. Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology 2010; 51:1445-1449. doi: 10.1002/hep.23478 PMID: 20077563
9. Sebastiani G. Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms. World J Gastroenterol 2009; 15:2190-2203. PMID: 19437558
10. Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2014. Aug 14. doi: 10.1002/hep.27368
11. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cisrrhosis: a systematic review of 118 studies. J Hepatol 2006; 44:217-231. PMID: 16298014
12. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012; 10:646-650. doi: 10.1016/j.cgh.2011.12.039 PMID: 22245962
13. Adams LA, Harmsen S, St Sauver JL, Charatcharoenwitthaya P, Enders FB, Therneau T, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 2010; 105:1567-1573. doi: 10.1038/ajg.2010.18 PMID: 20145609
14. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009; 49:1017-1044. doi: 10.1002/hep.22742 PMID: 19243014
15. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-526. PMID: 12883497
16. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-36. PMID: 17567829
17. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45:846-854. PMID: 17393509
18. Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, et al. Systematic review with meta-analysis: noninvasive assessment of non-alcoholic fatty liver disease-the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther 2014; 39:254-269. doi: 10.1111/apt.12569 PMID: 24308774
19. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29:1705-1713. PMID: 14698338
20. Sebastiani G, Tempesta D, Fattovich G, Castera L, Halfon P, Bourliere M, et al. Prediction of oesophageal varices in hepatic cirrhosis by simple serum non-invasive markers: Results of a multicenter, largescale study. Journal of hepatology 2010; 53:630-638. doi: 10.1016/j.jhep.2010.04.019 PMID: 20615567
21. Lee SS, Park SH, Kim HJ, Kim SY, Kim MY, Kim DY, et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. Journal of hepatology 2010; 52:579-585. doi: 10.1016/j.jhep.2010.01.008 PMID: 20185194
22. Al-Busafi SA, Ghali P, Wong P, Novales-Diaz JA, Deschenes M. The utility of Xenon-133 liver scan in the diagnosis and management of nonalcoholic fatty liver disease. Can J Gastroenterol 2012; 26:155-159. PMID: 22408767
23. Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010; 42:503-508. doi: 10.1016/j.dld.2009.08.002 PMID: 19766548
24. Vergniol J, Foucher J, Terrebonne E, Lee CH, Yang JI, Kim W, et al. Non-Invasive Tests for Fibrosis and Liver Stiffness Predict 5-Year Outcomes of Patients with Chronic Hepatitis C. Gastroenterology 2011; 140:1970-1979. doi: 10.1053/j.gastro.2011.02.058 PMID: 21376047
25. Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013; 145:782-789. doi: 10.1053/j.gastro.2013.06.057 PMID: 23860502
26. Kim BK, Kim HS, Yoo EJ, Oh EJ, Park JY, Kim do Y, et al. Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test. Hepatology 2014; 60:1911-1919. doi: 10.1002/hep.27389 PMID: 25142433
27. WHO. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. WHO Technical Report Series 894. Geneva: World Health Organization. 2000. PMID: 11234459
28. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366:1059-1062. PMID: 16182882
29. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128:1898-1906. PMID: 15940625
30. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94:2467-2474. PMID: 10484010
31. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313-1321. PMID: 15915461
32. Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, et al. A systematic review of followup biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 2013; 59:550-556. doi: 10.1016/j.jhep.2013.04.027 PMID: 23665288
33. Dunn MA, Behari J, Rogal SS, O'Connell MR, Furlan A, Aghayev A, et al. Hepatic steatosis in diabetic patients does not predict adverse liver-related or cardiovascular outcomes. Liver Int 2013; 33:1575-1582. doi: 10.1111/liv.12285 PMID: 23944954
34. Heimbach J. Debate: A bridge too far-liver transplantation for nonalcoholic steatohepatitis will overwhelm the organ supply. Liver Transpl 2014; 20 Suppl 2:S32-7. doi: 10.1002/lt.23980 PMID: 25155244
35. Klein EA, Thompson IM Jr., Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306:1549-1556. doi: 10.1001/jama.2011.1437 PMID: 21990298
36. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: highdosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142:37-46. PMID: 15537682
37. Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20:1712-1723. doi: 10.3748/wjg.v20.i7.1712 PMID: 24587650
38. Lakoff JM, Ellsmere J, Ransom T. Cause of death in patients awaiting bariatric surgery. Can J Surg 2015; 58:15-18. doi: 10.1503/cjs.002914 PMID: 25427334
39. Goossens N, Negro F. Insulin Resistance, Non-alcoholic Fatty Liver Disease and Hepatitis C Virus Infection. Rev Recent Clin Trials 2014. Dec 15.
40. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371:838-851. doi: 10.1016/S0140-6736(08)60383-9 PMID: 18328931
41. Child CG TJ. Surgery and portal hypertension. The liver and portal hypertension. Edited by Child CG. Philadelphia: Saunders 1964:50-64.
42. Shin SH, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, et al. Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis. Liver Int 2014 Jun 14.
43. Sebastiani G, Ghali P, Wong P, Klein MB, Deschenes M, Myers RP. Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey. Can J Gastroenterol Hepatol 2014; 28:23-30. PMID: 24416739